As previous studies demonstrated that dysregulation of glucose metabolism is linked to chemoresistance in cancer cells, we determined whether SHIP2 inhibition in HCC cells may affect the sensitivity of these cells to chemotherapy drugs. This evidence concerns the gene INPPL1 and cancer.